Answers are grounded in this paper and cite their sources.
In this issue of Blood, Guerra et al have excluded that growth differentiation factor 11 (GDF11) is the target of luspatercept, a novel drug that promotes differentiation of terminal erythropoiesis and is under evaluation for treatment of β-thalassemia and low-risk myelodysplastic syndromes (MDSs).1
No takes yet. Share an insight, caveat, or question.
Clara Camaschella (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: